NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, has announced that its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo ebolavirus and other Ebola viruses in the Democratic Republic of Congo (DRC) has been registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. This registration is a crucial step in the regulatory process, ensuring the trial's transparency and adherence to international standards.
The company previously received local regulatory approval from ACOREP to begin the trial and has stated that NV-387 has been delivered to the clinical trial site in Ituri province. First patient dosing is anticipated within one to two weeks, barring outbreak-related impediments. This timeline underscores the urgency and preparedness of the trial, which could offer a new therapeutic option in a region that has experienced recurrent Ebola outbreaks.
The adaptive trial design will commence with a single-arm safety and dose run-in phase, allowing researchers to assess the drug's safety and tolerability before progressing to a randomized, controlled, open-label efficacy evaluation. This two-stage approach is intended to efficiently gather data while ensuring patient safety. The trial's open-label nature means that both investigators and participants will know which treatment is administered, which could speed up the assessment of NV-387's effectiveness.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. Its oral formulation as gummies could significantly improve patient compliance and ease of administration compared to injectable therapies, particularly in resource-limited settings. The drug is also being evaluated in a Phase II clinical trial for Mpox in the DRC, highlighting its potential versatility across different viral threats.
The significance of this trial extends beyond Ebola. The successful development of an oral antiviral could transform outbreak response strategies, offering a more accessible and scalable intervention. Moreover, the trial's registration in a pan-African registry reflects a commitment to conducting research within the affected regions, which is vital for building local capacity and ensuring that treatments are suitable for the populations most in need.
NanoViricides' approach is based on its nanoviricide technology, which uses specially designed nanomaterials to target viruses. The company's lead candidate, NV-387, is also being developed for other viral infections, including respiratory syncytial virus (RSV), COVID-19, and influenza, among others. This broad-spectrum potential could position NV-387 as a critical asset in future pandemics and outbreaks.
The company has a Memorandum of Understanding with TheraCour Pharma, Inc., for the development of drugs based on these technologies for all antiviral infections. NanoViricides holds exclusive, sub-licensable field licenses to drugs developed in several licensed fields from TheraCour. This partnership provides a solid foundation for the company's pipeline.
For more information about NanoViricides, visit the company's newsroom at https://nnw.fm/NNVC.
